

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

OCI-Ly19

RRID:CVCL_1878

Type: Cell Line

Proper Citation

RRID:CVCL_1878

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1878

Proper Citation: RRID:CVCL_1878

Description: Cell line OCI-Ly19 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:8558920](#), [PMID:8574164](#), [PMID:19278952](#), [PMID:20054396](#), [PMID:20454443](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:23292937](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:26787899](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Caution: While it was indicated to be EBV-positive (PubMed=20454443), this result has later been shown to be invalid (personal communication of Uphoff, Cord C.)., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly19

Synonyms: OCI-LY19, OCI-LY-19, OCI-Ly 19, OCI Ly19, OCILY-19, OCILY19, OCILy19, Ly19, LY19

Cross References: CLO:CLO_0037052, EFO:EFO_0006709, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:974, BioSample:SAMN03471654, BioSample:SAMN10988474, cancercellines:CVCL_1878, Cell_Model_Passport:SIDM00460, ChEMBL-Cells:ChEMBL4482985, ChEMBL-Targets:ChEMBL4483262, CLS:305610, Cosmic:1079258, Cosmic:1086340, Cosmic:1295509, Cosmic:1329093, Cosmic:1629933, Cosmic:1945185, Cosmic:2276335, Cosmic-CLP:1330984, DepMap:ACH-000124, DSMZ:ACC-528, DSMZCellDive:ACC-528, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1330984, GEO:GSM380132, GEO:GSM552460, GEO:GSM887471, GEO:GSM888551, GEO:GSM1035326, GEO:GSM1374786, GEO:GSM1670298, IARC_TP53:30134, LiGeA:CCLE_704, LINCS_LDP:LCL-1121, PharmacDB:OCILY19_1186_2019, PRIDE:PXD030304, Progenetix:CVCL_1878, PubChem_Cell_line:CVCL_1878, Wikidata:Q54931771

ID: CVCL_1878

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260913T005647+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly19.

No alerts have been found for OCI-Ly19.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. European journal of immunology, 55(12), e70101.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Thuy AV, et al. (2021) Validation of a monoclonal antibody directed against the human sphingosine 1-phosphate receptor type 1. *Journal of immunological methods*, 490, 112953.

Carr M, et al. (2020) IKK γ and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKK γ /TBK1 inhibitor to repress NF- κ B and IL-10 signalling. *Journal of cellular and molecular medicine*, 24(19), 11573.

Park S, et al. (2020) Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. *Cancers*, 12(9).